Clinical and immunological aspects of treatment women with repeated in-vitro fertilization failure

Abstract

This review presents the existing literature concerning repeated implantation failure in assisted reproductive technologies. There are also discussed the role of immune pathology in the occurrence of repeated implantation failure in assisted reproductive treatment and the prospects of improving implantation rates with intravenous immunoglobulin in women with different immune pathologies.

Keywords

repeated implantation failure / repeated in-vitro fertilization failure / antiphospholipid syndrome / antiphospholipid antibodies / intravenous immunoglobulin / elevation of NK cell activities

References

[1] Achache H., Tsafrir A., Prus D., Reich R., Revel A. Defective endometrial prostaglandin synthesis identified in patients with repeated implantation failure undergoing in vitro fertilization. Fertil. Steril. 2010; 94; 1271-8.

[2] Backos M., Rai R., Regan L. Antiphospholipid antibodies and infertility. Hum. Fertil. 2002;5 (1): 30-4.

[3] Birkenfeld A. et al. Incidence of autoimmune antibodies in failed embryo transfer cycles. Am. J. Reprod. Immunol. 1994; 31: 65-8.

[4] Bleeker W. K., Teeling J. L., Hack C. E. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood. 2001;98 (10): 3136-42.

[5] Coulam C. B., Acacio B. Does immunotherapy for treatment of reproductive failure enhance live births? Am. J. Reprod. Immunol. 2012; 67: 296-03.

[6] Coulam C. B., Kaider B. D., Kaider A. S., Janowicz P., Roussev R. G. Antiphospholipid antibodies associated with implantation failure after IVF/ET. J. Assist. Reprod. Genet. 1997; 14: 603-8.

[7] Coulam C. B., Goodman C. Increased pregnancy rates after IVF/ET with intravenous immunoglobulin treatment in women with elevated circulating C56+ cells. Early Pregnancy. 2000; 4 (2): 90-8.

[8] Debrock S., Spiessens C., Peeraer K. et al. Higher implantation rate using modified quarter laser-assisted zona thinning in repeated implantation failure. Gynecol. Obstet. Invest. 2009; 67 (2): 127-33

[9] Denis A. L., Guido M., Adler R. D., Bergh P. A., Brenner C., Scott R. T. Jr. Antiphospholipid antibodies and pregnancy rates and outcome in IVF patients. Fertil. Steril. 1997; 67: 1084-90.

[10] Di Nisio M. et al. Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis. Blood. 2011; 118 (10): 2670-8.

[11] Elram T. et al. Treatment of recurrent IVF failure and human leukocyte antigen similarity by intravenous immunoglobulin. Reprod. Biomed. Online. 2005; 11 (6): 745-9.

[12] Firouzabadi R. D., Ghasemi N., Rozbahani M. A., Tabibnejad N. Association of p53 polymorphism with ICSI/IVF failure and recurrent pregnancy loss. Aust. N. Z. J. Obstet. Gynaecol. 2009; 49 (2): 216-9.

[13] Geva E., Yaron Y., Lessing J. B. et al. Circulating autoimmune antibodies may be responsible for implantation failure in in-vitro-fertilization. Fertil. Steril. 1994; 62: 802-6.

[14] Gleicher N., Liu H. C., Dudkiewicz A. et al. Autoantibody profiles and immunoglobulin levels as predictors of IVF success. Am. J. Obstet. Gynecol. 1994; 170: 1145-9.

[15] Gnoth C. et al. Final ART success rates: a 10 years survey. Hum. Reprod. 2011; 6 (8): 2239-46.

[16] Heilmann L., Schorsch M., Hahn T. CD3-CD56+CD16+ natural killer cells and improvement of pregnancy outcome in IVF/ICSI failure after additional IVIG-treatment. Am. J. Reprod. Immunol. 2010; 63 (3): 263-5.

[17] Hill J., Scott R. Immunological tests and IVF: “please, enough already.” Fertil. Steril. 2000;74: 439-42.

[18] Hornstein M. D., Davis O. K., Massey J. B., Paulson R. J., Collins J. A. Antiphospholipid antibodies and invitro fertilization success: a meta-analysis. Fertil. Steril. 2000;73:330-3.

[19] Huang S. Y. et al. Site-specific endometrial injury improves implantation and pregnancy in patients with repeated implantation failures. Reprod. Biol. Endocrinol. 9, 140.

[20] Huang S. Y., Wang C. J., Soong Y. K. et al. Site-specific endometrial injury improves implantation and pregnancy in patients with repeated implantation failures. Reprod Biol. Endocrinol. 2011; 9: 140.

[21] Kessel A., Ammuri H., Peri R. Intravenous immunoglobulin therapy affects t regulatory cells by increasing their suppressive function. J. Immunol. 2007;179 (8): 5571 -5.

[22] Kowalik A. et al. Midfollicular anticardiolipin and antiphosphatidylserine antibody titres do not correlate with in vitro fertilization outcome. Fertil. Steril. 1997; 68: 298- 04.

[23] Kupka M. S., Ferraretti A. P., de Mouzon J. et al. Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE. Hum Reprod. 2014; 29 (10): 2099-113.

[24] Kwak-Kim J., Han A. R., Gilman-Sachs A. et al. Current trends of reproductive immunology practices in in vitro fertilization (IVF) - a first world survey using IVF-Worldwide.com. Am. J. Reprod. Immunol. 2013; 69 (1): 12-20.

[25] Li J. et al. Intravenous immunoglobulin treatment for repeated IVF/ICSI failure and unexplained infertility: a systematic review and a meta-analysis. Am. J. Reprod. Immunol. 2013;70 (6): 434-47.

[26] Malizia B. A., Dodge L. E., Penzias A. S., Hacker M. R. The cumulative probability of liveborn multiples after in vitro fertilization: a cohort study of more than 10,000 women. Fertil Steril. 2013; 99 (2): 393-9.

[27] Mariee N. G. et al. The correlation of autoantibodies and uNK cells in women with reproductive failure. J. Reprod. Immunol. 2012; 95 (1-2): 59-66.

[28] Moraru M. et al. Intravenous immunoglobulin treatment increased live birth rate in a Spanish cohort of women with recurrent reproductive failure and expanded CD56 (+) cells. Am. J. Reprod. Immunol. 2012; 68 (1): 75-84.

[29] Polanski L. T. et al. What exactly do we mean by ‘recurrent implantation failure’? A systematic review and opinion. Reproductive BioMedicine Online. 2014; 28: 409-23.

[30] Sacks G. et al. Detailed analysis of peripheral blood natural killer cells in women with repeated IVF failure. Am J Reprod Immunol. 2012; 67 (5): 434-42.

[31] Sanmarco M. et al. Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization. Ann. N. Y. Acad. Sci. 2007;1108: 457-65.

[32] Sauer R., Roussev R., Jeyendran R. S., Coulam C. B. Prevalence of antiphospholipid antibodies among women experiencing unexplained infertility and recurrent implantation failure. Fertil Steril. 2010; 93 (7):2 441-3.

[33] Scher J., Salazar C. Clinical experience with IVIg Rx in patients with prior failed IVF pregnancies: report of 30 consecutive patients. Am. J. Reprod. Immunol. 2000; 44 (2): 121-4.

[34] Sermondade N., Delarouzière V., Ravel C. et al. Characterization of a recurrent poor-quality embryo morphology phenotype and zygote transfer as a rescue strategy. Reprod Biomed Online. 2012; 24 (4): 403-9.

[35] Sewell WAC and Jolles S. Immunomodulatory action of intravenous immunoglobulin//Immunology. - 2002. - December; 107 (4). - P. 387-393.

[36] Sher G. et al. The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. Am. J. Reprod. Immunol. 1998; 40 (2): 74-82.

[37] Sher G., Zouves C., Feinman M. et al. A rational basis for the use of combined heparin/aspirin and IVIG immunotherapy in the treatment of recurrent IVF failure associated with antiphospholipid antibodies. Am. J. Reprod. Immunol. 1998;39 (6):391-4.

[38] Stephenson M. D., Fluker M. R. Treatment of repeated unexplained in vitro fertilization failure with intravenous immunoglobulin: a randomized, placebo-controlled Canadian trial. Fertil. Steril. 2000;74 (6): 1108-13.

[39] Stern C. et al. Antibodies to β_2 glycoprotein I are associated with in vitro fertilization implantation failure as well as recurrent miscarriage: results of a prevalence study. Fertil. Steril. 1998; 70: 938-44.

[40] Tuckerman E. et al. Uterine natural killer cells in peri-implantation endometrium from women with repeated implantation failure after IVF. J. Reprod. Immunol. 2010; 87 (1-2): 60-6.

[41] Virro M. R., Winger E. E., Reed J. L. Intravenous immunoglobulin for repeated IVF failure and unexplained infertility. Am. J. Reprod. Immunol. 2012; 68 (3): 218-25.

[42] Winger E. E. Elevated preconception CD56+ 16+ and/or Th1: Th2 levels predict benefit from IVIG therapy in subfertile women undergoing IVF. Am. J. Reprod. Immunol. 2011; 66 (5): 394-03.

RIGHTS & PERMISSIONS

Krivonos M.I., Zaynulina M.S., Chepanov S.V., Selutin A.V., Selkov S.A., Mysik O.L.